Cargando…
329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma
BACKGROUND: Kaposi’s sarcoma (KS) is an AIDS-related condition that is mediated by HHV-8. Although incidence and mortality of KS in the United States have decreased over time since the advent of HAART, there may be disparities in mortality based on geographic location and race/ethnicity, particularl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810747/ http://dx.doi.org/10.1093/ofid/ofz360.402 |
_version_ | 1783462319566618624 |
---|---|
author | Knights, Sheena Lazarte, Susana Kainthla, Radhika Krieger, Demi Bhattatiry, Mitu Chiao, Elizabeth Nijhawan, Ank E Nijhawan, Ank E |
author_facet | Knights, Sheena Lazarte, Susana Kainthla, Radhika Krieger, Demi Bhattatiry, Mitu Chiao, Elizabeth Nijhawan, Ank E Nijhawan, Ank E |
author_sort | Knights, Sheena |
collection | PubMed |
description | BACKGROUND: Kaposi’s sarcoma (KS) is an AIDS-related condition that is mediated by HHV-8. Although incidence and mortality of KS in the United States have decreased over time since the advent of HAART, there may be disparities in mortality based on geographic location and race/ethnicity, particularly African-American men in the South. METHODS: A retrospective electronic medical record review was conducted using integrated inpatient and outpatient data in EPIC from PHHS. We included all individuals with a diagnosis of HIV and Kaposi’s sarcoma between January 1, 2009 and December 31, 2018 based on ICD-9/10 codes. We collected demographic information, HIV history, variables related to HIV and KS diagnosis, treatment and outcomes data for each patient. We calculated hazard ratios using Cox proportional hazards modeling. RESULTS: We identified 252 patients with KS. 95% of patients were male, and the majority were MSM (men who have sex with men; 77% of all patients). 35% of patients were Hispanic, 34% were African-American and 31% were Caucasian. Over half (56%) of patients were funded through Ryan White or were uninsured. The median CD4 count and viral load at the time of cancer diagnosis were 44 and 73,450, respectively. 24% of patients were confirmed to have died by the end of the study time frame. However, due to loss to follow-up, 35% of the cohort had an unknown vital status at the time of the final chart review. Variables most strongly associated with mortality were >2 hospitalizations in the first 6 months of cancer diagnosis (aHR=4.93, P = 0.0003), IV drug use (aHR=3.61, P = 0.0009), and T1 stage of KS (aHR= 2.13, P = 0.0264). African American patients had lower survival than Caucasian or Hispanic patients, with a 5-year survival of 69%, 81% and 80% respectively, although this did not reach statistical significance (aHR 1.77, P = 0.1396). CONCLUSION: We describe a large cohort of patients with HIV and HHV-8-related disease, who are predominantly of minority race/ethnicity, uninsured, and have advanced HIV disease. Factors associated with mortality include Black/African-American ethnicity, number of hospitalizations, IV drug use and T1 stage of KS. Our mortality analysis is limited due to high lost to follow-up rates, so we suspect overall mortality in our cohort is higher than currently reported. [Image: see text] DISCLOSURES: Ank E. Nijhawan, MD, MPH, Gilead Sciences, Inc.: Research Grant. |
format | Online Article Text |
id | pubmed-6810747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68107472019-10-28 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma Knights, Sheena Lazarte, Susana Kainthla, Radhika Krieger, Demi Bhattatiry, Mitu Chiao, Elizabeth Nijhawan, Ank E Nijhawan, Ank E Open Forum Infect Dis Abstracts BACKGROUND: Kaposi’s sarcoma (KS) is an AIDS-related condition that is mediated by HHV-8. Although incidence and mortality of KS in the United States have decreased over time since the advent of HAART, there may be disparities in mortality based on geographic location and race/ethnicity, particularly African-American men in the South. METHODS: A retrospective electronic medical record review was conducted using integrated inpatient and outpatient data in EPIC from PHHS. We included all individuals with a diagnosis of HIV and Kaposi’s sarcoma between January 1, 2009 and December 31, 2018 based on ICD-9/10 codes. We collected demographic information, HIV history, variables related to HIV and KS diagnosis, treatment and outcomes data for each patient. We calculated hazard ratios using Cox proportional hazards modeling. RESULTS: We identified 252 patients with KS. 95% of patients were male, and the majority were MSM (men who have sex with men; 77% of all patients). 35% of patients were Hispanic, 34% were African-American and 31% were Caucasian. Over half (56%) of patients were funded through Ryan White or were uninsured. The median CD4 count and viral load at the time of cancer diagnosis were 44 and 73,450, respectively. 24% of patients were confirmed to have died by the end of the study time frame. However, due to loss to follow-up, 35% of the cohort had an unknown vital status at the time of the final chart review. Variables most strongly associated with mortality were >2 hospitalizations in the first 6 months of cancer diagnosis (aHR=4.93, P = 0.0003), IV drug use (aHR=3.61, P = 0.0009), and T1 stage of KS (aHR= 2.13, P = 0.0264). African American patients had lower survival than Caucasian or Hispanic patients, with a 5-year survival of 69%, 81% and 80% respectively, although this did not reach statistical significance (aHR 1.77, P = 0.1396). CONCLUSION: We describe a large cohort of patients with HIV and HHV-8-related disease, who are predominantly of minority race/ethnicity, uninsured, and have advanced HIV disease. Factors associated with mortality include Black/African-American ethnicity, number of hospitalizations, IV drug use and T1 stage of KS. Our mortality analysis is limited due to high lost to follow-up rates, so we suspect overall mortality in our cohort is higher than currently reported. [Image: see text] DISCLOSURES: Ank E. Nijhawan, MD, MPH, Gilead Sciences, Inc.: Research Grant. Oxford University Press 2019-10-23 /pmc/articles/PMC6810747/ http://dx.doi.org/10.1093/ofid/ofz360.402 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Knights, Sheena Lazarte, Susana Kainthla, Radhika Krieger, Demi Bhattatiry, Mitu Chiao, Elizabeth Nijhawan, Ank E Nijhawan, Ank E 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma |
title | 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma |
title_full | 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma |
title_fullStr | 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma |
title_full_unstemmed | 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma |
title_short | 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma |
title_sort | 329. health disparities among hiv-positive patients with kaposi’s sarcoma |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810747/ http://dx.doi.org/10.1093/ofid/ofz360.402 |
work_keys_str_mv | AT knightssheena 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma AT lazartesusana 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma AT kainthlaradhika 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma AT kriegerdemi 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma AT bhattatirymitu 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma AT chiaoelizabeth 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma AT nijhawananke 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma AT nijhawananke 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma |